OTTAWA, Ontario, March 10, 2016 /PRNewswire/ -- VMS Rehab Systems Inc. (www.vmsrehabsystemsinc.com) announced today that the Company's BioPharmcor generic drug subsidiary has successfully expanded its roster of 'best of class' human capital to steer its generic drug business forward in the months and years ahead. Over the past 2 quarters, the Company has filled a number of key positions in both its European and North American operations.
At BioPharmcor BV, Amsterdam, The Netherlands, the parent Company of the BioPharmcor Group, Robert J. Wassink RA, has been designated as the Company's Chief Financial Officer(CFO).
Robert Wassink brings to BioPharmcor over 20 years of corporate business experience in finance, general management, asset, liability and enterprise risk management, corporate governance, strategy and project management. Mr. Wassink is a multilingual certified Dutch CPA (1998) with national and international expertise providing corporate financial management in The Americas, Europe, Asia Pacific, the Middle East and the Caribbean.
Prior to taking on the CFO responsibilities at the BioPharmcor Group, Mr. Wassink served as the Chief Financial Officer, Aruba Bank NV, the largest commercial bank in Aruba. In addition, he has held senior management positions at Deloitte Accountants, Amsterdam and HLB Schippers Tax and Legal Advisors, Amsterdam (currently BDO). Mr. Wassink is a principal of Bula Consulting, Amsterdam through which he provides his services to BioPharmcor and other clients.
At BioPharmcor Inc, a newly created Canadian subsidiary of BioPharmcor BV, Dr. Stuart Madden, PhD, CChem, FRSC will serve as BioPharmcor's Vice President, Pharmaceutical Development.
Dr. Madden has over 30 years' experience in the pharmaceutical industry. He is the Vice President of Scientific Affairs at ICON Clinical Research through which he will continue his work with BioPharmcor. Over the years, he has held a number of positions with several international pharmaceutical companies working on development programs from proof of concept through to commercialization.
Dr. Madden received his BS degree in chemistry and his PhD in physical chemistry from the University of Wales, Swansea, UK and was a Post-Doctoral Fellow at San Diego State University for two years. Dr. Madden has published in areas of adsorption mechanisms in chromatography, novel aspects of the degradation chemistry of morphine, and has contributed to texts on In Vitro-In Vivo correlations and has several patents approved/pending. He is a Chartered Chemist and Fellow of the Royal Society of Chemistry.
Working from BioPharmcor offices in both Amsterdam, The Netherlands and Warsaw, Poland, Dawid Mrotek will serve as the Company's Director, Investor Relations and Corporate Communications. Over the past 13 years, Mr. Mrotek has garnered a stellar reputation for building strategic investor networks through effective training and communications seminars and workshops. Since early in 2015, Mr. Mrotek has leveraged his many years of experience and know-how in the financial markets to assist BioPharmcor in meeting its funding goals in the development of the Company's generic tadalafil drug product. Mr. Mrotek has an EFC certificate from the European Federation of Financial Professionals. He holds the Chair position in UK-based consulting company Next2 Ltd.
In September 2015, BioPharmcor BV reported on the appointment of Dr. Anthony Bella, a leading world expert on urologic disorders in Men, as BioPharmcor's Chief Medical Officer (CMO). Dr. Bella currently serves as a Member of the Management Board of BioPharmcor BV and Poland based BioPharmcor Sp z o.o.
Amsterdam based BioPharmcor BV, is currently formulating and developing a line of drug products keyed to advancing men's health. The company has two operating subsidiaries, BioPharmcor Sp z o.o. in Warsaw, Poland and BioPharmcor Inc, in Ottawa, Canada.
VMS Rehab Systems Inc. was established as a Canadian incorporated company in 1998. In addition to controlling BioPharmcor BV, VMS Rehab Systems Inc. has been active in the home health market in North America for the past 18 years. More recently, the Company has been evaluating additional market opportunities to grow its business in the E-Health sector. VMS Rehab Systems Inc operates through its offices in Ottawa, Canada and affiliated BioPharmcor offices in Amsterdam, The Netherlands and Warsaw, Poland.
The shares of VMS Rehab Systems Inc. are quoted on the OTC Market 'pink current' symbol: VRSYF.
FORWARD-LOOKING INFORMATION: Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "will" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Corporation. The forward-looking information contained in this release is made as of the date hereof and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained here.
SOURCE VMS Rehab Systems Inc.